Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “First Line Metastatic Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00915603
What this trial is testing

Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
SCRI Development Innovations, LLC 113
Large-scale testing (Phase 3)Study completedNCT01526369
What this trial is testing

Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Cancer Trials Ireland 75
Not applicableLooking for participantsNCT06774027
What this trial is testing

Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

Who this might be right for
HER2-negative Breast CancerHER2 Negative Breast CarcinomaMetastatic Breast Cancer+3 more
University of California, San Francisco 100
Post-approval studies (Phase 4)UnknownNCT02207361
What this trial is testing

Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 120
Large-scale testing (Phase 3)Study completedNCT00448279
What this trial is testing

THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.

Who this might be right for
Breast Cancer
Hoffmann-La Roche 58
Large-scale testing (Phase 3)Active Not RecruitingNCT03997123
What this trial is testing

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

Who this might be right for
Triple Negative Breast Neoplasms
AstraZeneca 923
Large-scale testing (Phase 3)UnknownNCT04385563
What this trial is testing

Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.

Who this might be right for
HER2-positive Metastatic Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 338
Not applicableUnknownNCT02909361
What this trial is testing

Fulvestrant 500mg in Patients With Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Fudan University 500
Testing effectiveness (Phase 2)Ended earlyNCT00770354
What this trial is testing

Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer

Who this might be right for
Breast Carcinoma
Antisoma Research 110
Large-scale testing (Phase 3)Study completedNCT01663727
What this trial is testing

Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Hoffmann-La Roche 481
Testing effectiveness (Phase 2)Study completedNCT02668666
What this trial is testing

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

Who this might be right for
Hormone Receptor Positive Malignant Neoplasm of BreastHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastEstrogen Receptor Positive Breast Cancer+2 more
Oana Danciu, MD 49
Not applicableEnded earlyNCT05068726
What this trial is testing

Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients

Who this might be right for
Metastatic Breast Cancer
GE Healthcare 51
Large-scale testing (Phase 3)Study completedNCT00028990
What this trial is testing

Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Eastern Cooperative Oncology Group 722
Large-scale testing (Phase 3)Study completedNCT00002777
What this trial is testing

Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC 342
Testing effectiveness (Phase 2)UnknownNCT01196455
What this trial is testing

Capecitabine and Mitomycin C in Treatment of Patients With Metastatic Breast Cancer

Who this might be right for
Breast CancerMetastasis
Croatian Cooperative Group for Clinical Research in Oncology 39
Not applicableUnknownNCT06243432
What this trial is testing

Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer

Who this might be right for
Advanced Breast Carcinoma
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 600
Large-scale testing (Phase 3)Study completedNCT01989676
What this trial is testing

PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)

Who this might be right for
Metastatic Breast Cancer
Pfizer 707
Testing effectiveness (Phase 2)Ended earlyNCT01477060
What this trial is testing

Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Fondazione Michelangelo 32
Testing effectiveness (Phase 2)Ended earlyNCT01069796
What this trial is testing

Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer

Who this might be right for
Triple Negative Metastatic Breast Cancer
ARCAGY/ GINECO GROUP 64
Not applicableStudy completedNCT04394247
What this trial is testing

Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy

Who this might be right for
Breast Cancer
Pfizer 242
Next Page